SecBot SecBot
SECBOTREPLAY Home › Report › CABA

CABA · Cabaletta Bio reported Q4 and full-year 2025 financial results,…

Cabaletta Bio · PRESS-RELEASE filed Mar 23, 2026 at 07:30 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed Mar 23, 2026 at 07:30 ET

Cabaletta Bio reported Q4 and full-year 2025 financial results, highlighted by increased R&D spending and a cash position of $133.6 million, sufficient to fund operations into Q4 2026. The company reiterated key clinical milestones for rese-cel, including complete Phase 1/2 data readouts in 1H26 and a planned BLA submission for myositis in 2027.

  • R&D expenses increased to $36.2M (Q4 2025) from $25.5M (Q4 2024); full-year R&D rose to $142.7M from $97.2M.
  • G&A expenses decreased to $6.4M (Q4 2025) from $8.3M (Q4 2024).
  • Cash, cash equivalents, and short-term investments totaled $133.6M as of December 31, 2025, down from $164.0M a year prior.
  • Company raised an additional $30.0M in Q1 2026 via ATM sales and warrant exercises.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access